U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Vitalab Pharmacy, Inc. dba Vasco Rx Specialty Pharmacy - 570563 - 02/06/2020
  1. Warning Letters

CLOSEOUT LETTER

Vitalab Pharmacy, Inc. dba Vasco Rx Specialty Pharmacy MARCS-CMS 570563 —

Product:
Drugs
Recipient:
Recipient Name
Vladimir Lenchitsky
Recipient Title
Founder and Chairman of the Board
Vitalab Pharmacy, Inc. dba Vasco Rx Specialty Pharmacy

4045 E. Bell Rd.
Suite 163
Phoenix, AZ 85032
United States

Issuing Office:
Division of Pharmaceutical Quality Operations IV

United States

949-608-2900

Dear Mr. Lenchitsky :

The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter (WL# 570563) dated January 10, 2019. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.

You are expected to take all necessary steps to ensure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/
CDR Steven E Porter, Jr.
Director, Division of Pharmaceutical Quality Operations IV

Back to Top